SCHEMBL2872060

SCHEMBL2872060

COC(=O)c1cc(S(C)(=O)=O)ccc1Cl

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.68
ALDH1A1 P00352 4/20 0.65
TSHR P16473 1/20 0.65
GAA P10253 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
MAPT P10636 4/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 1/20 0.46
USP28 Q96RU2 1/20 0.45
PTGS2 P35354 2/20 0.45
SMO Q99835 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8259017 0.87 ALDH1A1 (0.62) LMNAALDH1A1TSHRGAAL3MBTL1
SCHEMBL18547926 0.87 ALDH1A1 (0.65) LMNAALDH1A1TSHRGAAL3MBTL1
SCHEMBL1258694 0.87 LMNA (0.54) LMNAALDH1A1TSHRGAAMEN1
SCHEMBL1185698 0.85 ALDH1A1 (0.63) LMNAALDH1A1TSHRGAAL3MBTL1
SCHEMBL4946040 0.84 ALDH1A1 (0.62) LMNAALDH1A1TSHRGAAL3MBTL1
SCHEMBL9658929 0.81 LMNA (0.61) LMNAALDH1A1TSHRGAAL3MBTL1
SCHEMBL2642601 0.81 LMNA (0.47) LMNAALDH1A1TSHRGAAMEN1
SCHEMBL2642603 0.81 CA2 (0.61) LMNAALDH1A1TSHRGAAMEN1
SCHEMBL8350642 0.81 LMNA (0.47) LMNAALDH1A1TSHRSMN1; SMN2NPSR1
SCHEMBL4939310 0.81 LMNA (0.49) LMNAALDH1A1TSHRGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188070-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2025-06-12 US disclosed
CN-112236428-B Antiproliferative compounds and uses thereof 默克专利股份有限公司 2025-04-01 CN disclosed
US-12195453-B2 Antiproliferation compounds and uses thereof MERCK PATENT GMBH (DE) 2025-01-14 US disclosed
US-20240269293-A1 PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF OD THERAPEUTICS LIMITED (CN) 2024-08-15 US disclosed
EP-4043460-B1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2024-06-05 EP disclosed
EP-4313154-A1 PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF OD Therapeutics Limited (HK) 2024-02-07 EP disclosed
CN-117355337-A Protein-macromolecule conjugates and methods of use thereof 奥迪曼药业科技有限公司 2024-01-05 CN disclosed
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-05-18 US disclosed
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-05-18 US disclosed
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-05-18 US disclosed
US-20080090822-A1 Piperazine Derivatives As Glyt 1 Inhibitors GLAXO GROUP LIMITED 2008-04-17 US disclosed
US-20080090822-A1 Piperazine Derivatives As Glyt 1 Inhibitors GLAXO GROUP LIMITED 2008-04-17 US disclosed
EP-1858869-A1 ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
EP-1856077-A1 PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS GLAXO GROUP LIMITED (GB) 2007-11-21 EP disclosed
WO-2006094842-A1 ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed
WO-2006094840-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed
WO-2006094843-A1 PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed
WO-2006094843-A1 PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed
US-20060167246-A1 Thienopyrrole compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2006-07-27 US disclosed
US-6001881-A Ortho-substituted benzoylguanidines, a process for their preparation, their use as a medicament or diagnostic agent, and a medicament comprising them HOECHST AKTIENGESELLSCHAFT (DE) 1999-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240269293-A1 PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF CD44, MACROD1, MSN LMNA 1994/4885ALDH1A1 2362/4885TSHR 3309/4885
US-20080090822-A1 Piperazine Derivatives As Glyt 1 Inhibitors SLC6A7, SLC6A5, SLC1A2 LMNA 4438/4885ALDH1A1 1381/4885TSHR 1584/4885
US-20060167246-A1 Thienopyrrole compound and use thereof as HCV polymerase inhibitor TPMT, JAK2, GTF3C5 LMNA 4828/4885ALDH1A1 351/4885TSHR 2758/4885
US-12195453-B2 Antiproliferation compounds and uses thereof MKI67, MCL1, CCNI LMNA 1520/4885ALDH1A1 263/4885TSHR 3810/4885
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI LMNA 1520/4885ALDH1A1 263/4885TSHR 3810/4885
US-20250188070-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI LMNA 1520/4885ALDH1A1 263/4885TSHR 3810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.